ScoreComparison
Why is Aligos Therapeutics, Inc. ?
1
Negative results in Jun 25
- NET SALES(HY) At USD 1.28 MM has Grown at -37.66%
- NET PROFIT(9M) At USD -71.91 MM has Grown at -24.64%
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -52.79%, its profits have risen by 31.2%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -3.8% over the previous quarter and currently hold 2.86% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -52.79% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Aligos Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Aligos Therapeutics, Inc.
-62.28%
-0.26
109.49%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.54%
EBIT Growth (5y)
6.91%
EBIT to Interest (avg)
-103.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.15
Sales to Capital Employed (avg)
0.12
Tax Ratio
22.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.38
EV to EBIT
1.05
EV to EBITDA
1.07
EV to Capital Employed
5.01
EV to Sales
-27.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
478.69%
ROE (Latest)
-58.88%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET PROFIT(HY)
Higher at USD -35.89 MM
RAW MATERIAL COST(Y)
Fallen by -73.84% (YoY
OPERATING PROFIT(Q)
Highest at USD -18.31 MM
-10What is not working for the Company
NET SALES(HY)
At USD 1.28 MM has Grown at -37.66%
NET PROFIT(9M)
At USD -71.91 MM has Grown at -24.64%
Here's what is working for Aligos Therapeutics, Inc.
Net Profit
Higher at USD -35.89 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -18.31 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Raw Material Cost
Fallen by -73.84% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Aligos Therapeutics, Inc.
Net Sales
At USD 1.28 MM has Grown at -37.66%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
